Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

7.770 +0.270 (+3.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MeiraGTx Holdings plc - Ordinary Shares

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Crude Oil Falls 1%; Dollar General Posts Upbeat Sales
Via Benzinga
Exposures Fossil Fuels
G-III Apparel Posts Better-Than-Expected Earnings, Joins Ballard Power Systems, Dollar General And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Recap: MeiraGTx Hldgs Q4 Earnings
Via Benzinga
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars
MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
From MeiraGTx
Via GlobeNewswire
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary... 
From MeiraGTx
Via GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
Jim Cramer: This Tech Stock Is A Buy, SoFi Technologies Is Good
SoFi Technologies, Inc. is good, Jim Cramer said. It reported third-quarter adjusted sales of $689.445 million, according to Benzinga Pro. 
Via Benzinga
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms 
From MeiraGTx
Via GlobeNewswire
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
Via Benzinga
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints
MeiraGTx's clinical study of AAV-GAD for Parkinson's disease showed significant improvements in motor function and quality of life in high- and low-dose groups, with no serious adverse events.... 
Via Benzinga
Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Walgreens Posts Upbeat Earnings, Joins Wolfspeed, Ericsson And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency 
From MeiraGTx
Via GlobeNewswire
MGTX Stock Earnings: MeiraGTx Hldgs Misses EPS, Misses Revenue for Q2 2024
MGTX stock results show that MeiraGTx Hldgs missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
From MeiraGTx
Via GlobeNewswire
Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose
Cramer recommends staying away from Canada Goose, even though it reported better-than-expected Q4 earnings. 
Via Benzinga
MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q1 2024
MGTX stock results show that MeiraGTx Hldgs beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
From MeiraGTx
Via GlobeNewswire
MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023
MGTX stock results show that MeiraGTx Hldgs beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.